Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220947 · ClinicalTrials.gov registry record · Phase 2
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
A Phase 2 study of Hepatitis C, Chronic, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 421
- Enrollment target
- 20
- Study locations
NCT01220947: Completed Phase 2 study of Hepatitis C, Chronic, sponsored by Hoffmann-La Roche.
NCT01220947 is a Phase 2 study of Hepatitis C, Chronic that has completed, run by Hoffmann-La Roche. The registered enrollment target is 421 participants, above the 360-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01220947, a Phase 2 study of Hepatitis C, Chronic, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 421 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus versus Pegasys and Copegus alone in treatment-naive patients with chronic Hepatitis C.
Conditions Studied
Interventions
- DRUG Copegus
- DRUG Danoprevir
- DRUG Pegasys
Study Locations (20)
California
- - La Jolla
- - Sacramento
- - San Diego
- - San Francisco
Florida
- - Orlando
- - Orlando
- - South Miami
New York
- - Manhasset
- - New York
- - The Bronx
North Carolina
- - Chapel Hill
- - Fayetteville
Colorado
- - Aurora
Georgia
- - Decatur
Hawaii
- - Honolulu
Illinois
- - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01220947 record still lists
NCT01220947 is an interventional study that assigns participants to a tested intervention. The registered 421 participants enrollment target is mid-sized for trials with a published cap, above the 360-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 3 interventions - of which Copegus is the first listed.
NCT01220947 names 20 study sites across 12 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01220947 about?
NCT01220947 is a clinical study titled "A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection". This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus versus Pegasys and Copegus alone in treatment-naive patients with chroni...
What is the current status of trial NCT01220947?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 421 participants. The study started on 2010-11. Estimated completion is 2012-12.
What conditions does trial NCT01220947 study?
This clinical trial studies the following conditions: Hepatitis C, Chronic.
What interventions are being tested in trial NCT01220947?
The interventions under investigation include: Copegus (DRUG), Danoprevir (DRUG), Pegasys (DRUG).
Who is sponsoring clinical trial NCT01220947?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01220947 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01220947's enrollment target sits among peer trials
421 4th of 26 higher than 23 of 26 other Hepatitis C, Chronic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
-
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
COMPLETED · Phase 2
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
COMPLETED · Phase 2
-
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
COMPLETED · Phase 2
-
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05976763 · 421 participants · Phase 3
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- NCT07114601 · 421 participants · Phase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT06837246 · 422 participants · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia